Licence agreement for TGR immunoassay technology
Adelaide biotechnology company TGR BioSciences has announced a European licence agreement with Prime Diagnostics, part of Wageningen UR in the Netherlands — a developer of high-quality diagnostics, technologies and services for the agricultural sector.
The licence agreement will provide non-exclusive access to TGR’s CaptSure technology for use in its immunoassay products for the agricultural sector. TGR will also provide antibody conjugation services, which will allow Prime Diagnostics to access the former’s antibody tagging and immobilisation technology.
In comparison to conventional assays, which usually involve three separate incubations over 2–3 days or more, CaptSure technology only requires a single incubation period and can be performed within an hour, without compromising sensitivity or quality. The simple and robust format of the technology is said to reduce the cost of labour in medium- and high-throughput screening laboratories and to deliver more flexibility for planning of QA/QC operations to the industry.
“Our tests, using CaptSure immunoassays to find key plant virus targets, have shown the TGR system to be sensitive and fast,” said Jose van Beckhoven, product manager, Prime Diagnostics.
“Prime Diagnostics is very pleased to be an early adopter of this technology to bring next-generation products to the potato, horticultural and ornamental industry for virus and bacteria detection.”
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
